Celiac disease: from pathogenesis to novel therapies
- PMID: 19766641
- DOI: 10.1053/j.gastro.2009.09.008
Celiac disease: from pathogenesis to novel therapies
Abstract
Celiac disease has become one of the best-understood HLA-linked disorders. Although it shares many immunologic features with inflammatory bowel disease, celiac disease is uniquely characterized by (1) a defined trigger (gluten proteins from wheat and related cereals), (2) the necessary presence of HLA-DQ2 or HLA-DQ8, and (3) the generation of circulating autoantibodies to the enzyme tissue transglutaminase (TG2). TG2 deamidates certain gluten peptides, increasing their affinity to HLA-DQ2 or HLA-DQ8. This generates a more vigorous CD4(+) T-helper 1 T-cell activation, which can result in intestinal mucosal inflammation, malabsorption, and numerous secondary symptoms and autoimmune diseases. Moreover, gluten elicits innate immune responses that act in concert with the adaptive immunity. Exclusion of gluten from the diet reverses many disease manifestations but is usually not or less efficient in patients with refractory celiac disease or associated autoimmune diseases. Based on the advanced understanding of the pathogenesis of celiac disease, targeted nondietary therapies have been devised, and some of these are already in phase 1 or 2 clinical trials. Examples are modified flours that have been depleted of immunogenic gluten epitopes, degradation of immunodominant gliadin peptides that resist intestinal proteases by exogenous endopeptidases, decrease of intestinal permeability by blockage of the epithelial ZOT receptor, inhibition of intestinal TG2 activity by transglutaminase inhibitors, inhibition of gluten peptide presentation by HLA-DQ2 antagonists, modulation or inhibition of proinflammatory cytokines, and induction of oral tolerance to gluten. These and other experimental therapies will be discussed critically.
Similar articles
-
Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells.J Immunol. 2009 Jun 15;182(12):7440-50. doi: 10.4049/jimmunol.0900233. J Immunol. 2009. PMID: 19494267
-
Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice.Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G217-25. doi: 10.1152/ajpgi.00225.2007. Epub 2007 Nov 15. Am J Physiol Gastrointest Liver Physiol. 2008. PMID: 18006603
-
Celiac disease: risk assessment, diagnosis, and monitoring.Mol Diagn Ther. 2008;12(5):289-98. doi: 10.1007/BF03256294. Mol Diagn Ther. 2008. PMID: 18803427 Review.
-
Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management.Nutr Clin Care. 2005 Apr-Jun;8(2):54-69. Nutr Clin Care. 2005. PMID: 16013224 Review.
-
Celiac disease--sandwiched between innate and adaptive immunity.Hum Immunol. 2006 Jun;67(6):460-8. doi: 10.1016/j.humimm.2006.03.011. Epub 2006 Mar 30. Hum Immunol. 2006. PMID: 16728270 Review.
Cited by
-
Development of celiac-safe foods: prevention of transglutaminase 2 (TG2) deamidation of gluten in healthy non-celiac volunteers.Front Nutr. 2024 Mar 14;11:1308463. doi: 10.3389/fnut.2024.1308463. eCollection 2024. Front Nutr. 2024. PMID: 38549745 Free PMC article.
-
Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease.Pharmaceuticals (Basel). 2023 Dec 20;17(1):4. doi: 10.3390/ph17010004. Pharmaceuticals (Basel). 2023. PMID: 38275990 Free PMC article. Review.
-
Clinical and demographic comparison of celiac disease diagnosed during adulthood versus childhood and adolescence: A single-center experience.JGH Open. 2023 Nov 30;7(12):923-927. doi: 10.1002/jgh3.13003. eCollection 2023 Dec. JGH Open. 2023. PMID: 38162861 Free PMC article.
-
Dynamics of Serologic Change to Gluten in Celiac Disease Patients.Nutrients. 2023 Dec 12;15(24):5083. doi: 10.3390/nu15245083. Nutrients. 2023. PMID: 38140342 Free PMC article.
-
The Contribution of the Intestinal Microbiota to the Celiac Disease Pathogenesis along with the Effectiveness of Probiotic Therapy.Microorganisms. 2023 Nov 23;11(12):2848. doi: 10.3390/microorganisms11122848. Microorganisms. 2023. PMID: 38137992 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials